证券代码：300247 证券简称：融捷健康 公告编号：2023－031 融捷健康科技股份有限公司 关于董事长辞职暨选举董事长的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记 载、误导性陈述或重大遗漏。 一、董事长辞职情况 融捷健康科技股份有限公司（以下简称"公司"）董事会于 2023 年 9 月 10 日收到公司董事长吕向阳先生的辞职报告，吕向阳先生由于个人原因，申请 辞去公司第六届董事会董事长职位。吕向阳先生辞职后仍担任公司第六届董事 会董事、董事会战略委员会委员职务，其辞职不会对公司日常管理和生产经营 产生不利影响。 根据《公司法》及《公司章程》的有关规定，吕向阳先生的辞职报告自送 达公司董事会之日起生效。截至本公告披露日，吕向阳先生通过融捷投资控股 集团有限公司（以下简称"融捷集团"）持有公司股份 116,912,302 股。吕向 阳先生为融捷集团的董事长、实际控制人，并在融捷集团控制的企业担任董事 等职务，同时也是本公司的实际控制人。吕向阳先生所持有的公司股份将继续 严格按照中国证监会《上市公司股东、董监高减持股份的若干规定》、深圳证 券交易所《上市公司股东及董事、监事、高级管 ...

第六届董事会第六次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记 载、误导性陈述或重大遗漏。 融捷健康科技股份有限公司（以下简称"公司"、"融捷健康"）第六届董事 会第六次会议通知于 2023 年 09 月 05 日以电子邮件的形式向各位董事发出。本 次会议于 2023 年 09 月 11 日上午以现场结合通讯的方式召开，会议由吕向阳先 生主持，本次会议应出席会议董事 6 人，实际出席会议董事 6 人。本次会议的 召集、召开及表决程序符合《公司法》等相关法律法规以及《公司章程》的有 关规定；本次会议决议合法、有效。 一、审议通过《关于选举公司董事会董事长的议案》 董事会同意选举邢芬玲女士为公司第六届董事会董事长，任期自公司董事 会决议通过之日起至公司第六届董事会届满之日止，简历见附件。 表决结果：6 票同意，0 票反对，0 票弃权。 证券代码：300247 证券简称：融捷健康 公告编号：2023－030 融捷健康科技股份有限公司 1 证券代码：300247 证券简称：融捷健康 公告编号：2023－030 简历 邢芬玲女士：1976 年 3 月出生，中国国籍，无境外永久居留权，本 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥271,201,740.22, representing a 14.85% increase compared to ¥236,139,674.37 in the same period last year[22]. - The net profit attributable to shareholders of the listed company decreased by 84.35% to ¥21,039,872.14 from ¥134,454,066.66 year-on-year[22]. - The basic earnings per share dropped by 84.33% to ¥0.0262 from ¥0.1672 in the same period last year[22]. - The company reported a significant increase of 510.99% in net profit attributable to shareholders after deducting non-recurring gains and losses, reaching ¥20,588,582.07 compared to ¥3,369,696.98 in the previous year[22]. - The company's revenue for the reporting period was ¥271,201,740.22, representing a 14.85% increase compared to ¥236,139,674.37 in the same period last year, primarily driven by significant sales growth in the U.S. subsidiary[47]. - The company reported a net profit of ¥32,049,786.72, a decrease of 77.53% from ¥142,630,573.32 in the first half of 2022[143]. - The company's total comprehensive income for the first half of 2023 was ¥5,314,515.77, a decrease of 95.8% from ¥127,806,275.31 in the first half of 2022[147]. Cash Flow and Assets - The net cash flow from operating activities improved significantly to ¥82,330,869.57, compared to a negative cash flow of ¥22,738,460.30 in the previous year, marking a 462.08% increase[22]. - Cash and cash equivalents increased to ¥124,865,348.03, representing 10.41% of total assets, up from 5.75% last year, primarily due to increased sales collections from the U.S. subsidiary[54]. - The company's total assets at the end of the reporting period were ¥1,199,742,928.69, a slight increase of 1.09% from ¥1,186,803,628.67 at the end of the previous year[22]. - The total current liabilities decreased to CNY 105,210,754.85 from CNY 125,128,626.30, a reduction of about 16%[138]. - The total cash and cash equivalents at the end of the period stood at 24,108,279.70 CNY, down from 47,583,610.41 CNY at the beginning of the year, reflecting a decrease of approximately 49.5%[154]. Investments and R&D - The company reported a profit from investment activities of ¥1,054.47 million from low-risk financial products during the reporting period[40]. - The company has allocated 1,150 million yuan for research and development in new technologies[163]. - Research and development expenses for the first half of 2023 were ¥3,917,368.56, a decrease of 28.36% compared to ¥5,482,946.98 in the previous year[143]. Market and Product Development - The company has successfully expanded its market presence, with a notable increase in orders from Australia following the acquisition of SAA certification and a foundation laid for Japanese orders with PSE certification[31]. - The company has accelerated new product development, resulting in the mass production of new sauna products using carbonized wood and outdoor sauna rooms, which helped mitigate the decline in demand for traditional products[32]. - The company plans to accelerate new product development and optimize product structure to enhance competitiveness[82]. Financial Health and Risks - The company has no interest-bearing debt, indicating strong financial health and the ability to withstand economic challenges[42]. - The company faces risks from macroeconomic conditions, market competition, and raw material price fluctuations, with strategies to mitigate these risks[82][83]. - The company has outlined potential risks and corresponding measures in its management discussion and analysis section, which investors are encouraged to review[4]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[5]. - The total number of shares is 804,040,313, with 99.90% being unrestricted shares[120]. - The largest shareholder, Rongjie Investment Holding Group, holds 14.54% of the shares, totaling 116,912,302 shares[122]. Compliance and Governance - The semi-annual financial report has not been audited[98]. - The company has not reported any significant environmental issues or administrative penalties during the reporting period[92]. - The company has not engaged in any major related party transactions during the reporting period[102]. Future Outlook - The company has not disclosed specific future outlook or guidance figures in the provided documents, indicating a cautious approach to forecasting[155]. - Future guidance indicates a projected revenue growth of 10% for the next fiscal year[161].

本公司及董事会全体成员保证公告内容真实、准确、完整，不存在虚假记 载、误导性陈述或重大遗漏。 证券代码：300247 证券简称：融捷健康 公告编号：2023－028 融捷健康科技股份有限公司 第六届董事会第五次会议决议公告 《2023 年半年度募集资金存放与使用情况的专项报告》具体内容详见刊登 于中国证监会指定创业板信息披露的网站（www.cninfo.com.cn）的相关公告。 1 融捷健康科技股份有限公司（以下简称"公司"、"融捷健康"）第六届董事 会第五次会议通知于 2023 年 08 月 18 日以电子邮件的形式向各位董事发出。本 次会议于 2023 年 08 月 28 日上午以现场结合通讯的方式召开，会议由董事长吕 向阳先生主持，本次会议应出席会议董事 6 人，实际出席会议董事 6 人。本次 会议的召集、召开及表决程序符合《公司法》等相关法律法规以及《公司章程》 的有关规定；本次会议决议合法、有效。 一、审议通过《关于公司<2023年半年度报告>及其摘要的议案》 董事会认为：公司编制《2023 年半年度报告》及其摘要的程序符合法律、 行政法规和中国证监会的规定，报告内容公允地反映了公司的经营状况和经 ...

融捷健康科技股份有限公司 2023 年半年度募集资金存放与使用情况的专项报告 根据深圳证券交易所印发的《深圳证券交易所创业板上市公司规范运作指引》 和相关格式指引的规定，融捷健康科技股份有限公司（以下简称"本公司"、"公 司"）将 2023 年半年度募集资金存放与使用情况报告如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 经中国证券监督管理委员会《关于核准融捷健康科技股份有限公司向潘建忠 等发行股份购买资产并募集配套资金的批复》（证监许可[2016]2053 号）核准， 公司于 2016 年 11 月 8 日向潘建忠、黄小霞合计发行股份 19,444,444 股、支付现 金 8,200 万元购买相关资产；向陈伟、李江合计发行股份 15,555,556 股、支付现 金 6,360 万元购买相关资产；并于 2016 年 11 月 8 日向特定投资者鹏华资产管理 （深圳）有限公司、安徽皖投工业投资有限公司、安徽高新毅达皖江产业发展创 业投资基金（有限合伙）、新华基金管理股份有限公司、财通基金管理有限公司 发行人民币普通股 47,507,953 股（以上每股发行价均为人民币 9.43 元）募集配 ...

融捷健康科技股份有限公司独立董事 关于公司第六届董事会第五次会议相关事项的独立意见 根据中国证监会《关于在上市公司建立独立董事制度的指导意见》、《深圳 证券交易所创业板股票上市规则》、《深圳证券交易所创业板上市公司规范运作 指引》及《公司章程》、《独立董事工作制度》等有关规定和要求，我们作为融 捷健康科技股份有限公司（以下简称"公司"）的独立董事，本着对公司、全体 股东认真负责的态度，对公司关于第六届董事会第五次会议相关事项进行了认真 审议并发表了如下独立意见： 二、关于公司对外担保情况的独立意见 报告期内，公司不存在为股东、股东控股的子公司、股东的附属企业及其他 关联方、任何非法人单位或个人提供担保的情况，符合中国证监会《关于规范上 市公司对外担保行为的通知》、《深圳证券交易所创业板上市公司规范运作指引》 及《公司章程》等有关规定。 三、关于公司2023年半年度募集资金存放与使用情况的独立意见 一、关于控股股东及其他关联方占用公司资金情况的独立意见 报告期内，公司与控股股东及其他关联方的资金往来能够严格遵守相关规定， 不存在控股股东及其他关联方非经营性占用公司资金的情况。 经核查，公司 2023 年半年度募 ...

| | | 触捷健康2023年半年度 | | 非经营性资金占用及其他关联资金往来情况汇总 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | इस ब्रहरू र 小计 空股形 | 06 登金占用方に移 | 上市公司核算的会 用方与上市公司 的关联关系 | 自 2023年期初占用资 2023年度占用量计 2023年期初占用资 发生金额（不含利 金余额 | 2023年度占用资金 2023年度偿还累计 2023年期末占 的利息（如有） 发生金额 | | 用形成原 | 单位:元 与用性质 | | 控股股东、实际控 人及非附属企业 小计 小计 其他关联方及其附属 | | | | | | | | | 总书 他关联资金往 | 金往来方名 | 上市公司核算的会 计科目 来方与上市公 的关联关系 | 2023年度往来累 发生金额（不含 2023年期初往来资 金余额 | 2023年度偿还累计 2023年期末往 发生金额 2023年度占用资金 的利息(如有 | 金余额 | 主来形成原 | E来性质（经营 | | 股股东、实际控制 一及其时后个 | | | 息) ...

证券代码：300247 证券简称：融捷健康 公告编号：2023－029 融捷健康科技股份有限公司 第六届监事会第四次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏。 融捷健康科技股份有限公司（以下简称"公司"）第六届监事会第四次会议通知于 2023 年 08 月 18 日以电子邮件方式发出，本次会议于 2023 年 08 月 28 日上午在融捷 健康合肥总部三楼会议室以现场结合通讯方式召开。会议由监事会主席贾小慧女士主 持，本次应出席会议的监事 3 人，实际出席会议的监事 3 名。本次会议符合《公司法》 及《公司章程》的有关规定。 一、审议通过《关于公司<2023年半年度报告>及其摘要的议案》 监事会认为：公司编制《2023 年半年度报告》及其摘要的程序符合法律、行政法 规和中国证监会的规定，报告内容公允地反映了公司的经营状况和经营成果，报告所 披露的信息真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏。 《2023年半年度报告》及《2023年半年度报告摘要》具体内容详见刊登于中国证 监会指定创业板信息披露的网站（www.cninfo.com.c ...

Financial Performance - The company's revenue for Q1 2023 was ¥158,259,198.06, representing a 28.43% increase compared to ¥123,228,041.25 in the same period last year[5] - Net profit attributable to shareholders was ¥11,189,537.80, a significant increase of 116.73% from ¥5,162,844.88 year-on-year[5] - Basic earnings per share rose to ¥0.0139, up 117.19% from ¥0.0064 in the same period last year[5] - The company's net profit for the current period is CNY 18,327,304, representing an increase of 48.3% compared to CNY 12,373,896.73 in the previous period[25] - Operating profit increased to CNY 25,233,202.51, up 31.1% from CNY 19,238,586.03 year-over-year[25] - Total revenue from sales of goods and services reached CNY 149,863,285.01, an increase of 13.9% compared to CNY 131,546,519.87 in the previous period[28] - The total comprehensive income for the current period is CNY 16,808,961.24, compared to CNY 12,208,652.83 in the previous period[26] Cash Flow - The net cash flow from operating activities surged to ¥46,906,552.61, marking a 635.77% increase from ¥6,375,180.75 in the previous year[5] - The net cash flow from operating activities improved significantly to CNY 46,906,552.61, compared to CNY 6,375,180.75 in the previous period[28] - Investment activities generated a net cash flow of CNY 3,368,744.96, a turnaround from a negative cash flow of CNY -13,885,986.01 in the previous period[29] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,185,304,298.39, a slight decrease of 0.13% from ¥1,186,803,628.67 at the end of the previous year[5] - The company's total assets decreased slightly to CNY 1,185,304,298.39 from CNY 1,186,803,628.67 at the beginning of the year[23] - The total liabilities decreased to CNY 139,722,035.41 from CNY 158,030,326.94, showing a reduction of approximately 11.6%[23] - The total equity attributable to the parent company increased to CNY 998,626,593.49 from CNY 988,955,398.44, reflecting a growth of 1.7%[23] Operating Costs and Expenses - The company reported a 39.72% increase in operating costs, amounting to an increase of ¥31,636,500.00 due to higher sales from its U.S. subsidiary[12] - The total operating costs amounted to CNY 137,305,140.63, up from CNY 105,672,960.28, reflecting a year-over-year increase of 29.9%[24] - Research and development expenses were CNY 2,065,738.44, a decrease of 22.5% from CNY 2,667,178.09 in the previous period[25] Inventory and Accounts Payable - Inventory decreased by ¥45,585,600.00, reflecting a 24.43% decline, mainly due to sales of previously held inventory by the U.S. subsidiary[10] - The company reported a decrease in inventory from CNY 186,574,736.48 to CNY 140,989,089.00, a reduction of approximately 24.4%[22] - The accounts payable decreased from CNY 52,696,877.97 to CNY 40,690,282.01, indicating a decline of about 22.8%[23] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 38,439[17] Foreign Currency and Other Adjustments - The company reported a foreign currency translation difference of CNY -986,922.79, compared to CNY -165,243.90 in the previous period[26]

Financial Performance - The company's operating revenue for 2022 was approximately ¥463.32 million, a decrease of 12.00% compared to ¥526.50 million in 2021[24]. - The net profit attributable to shareholders for 2022 was approximately ¥126.31 million, representing a significant increase of 421.87% from ¥24.20 million in 2021[24]. - Basic earnings per share for 2022 were ¥0.16, an increase of 433.33% from ¥0.03 in 2021[24]. - The total assets at the end of 2022 were approximately ¥1.19 billion, an increase of 16.11% from ¥1.02 billion at the end of 2021[24]. - The net assets attributable to shareholders at the end of 2022 were approximately ¥988.96 million, an increase of 18.95% from ¥831.43 million at the end of 2021[24]. - The company reported a weighted average return on equity of 14.12% for 2022, up from 2.95% in 2021, indicating improved profitability[24]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year, representing a 20% year-over-year growth[117]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in Q3 2023, representing a 25% year-over-year growth[118]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25%[117]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 20% to 1.8 billion RMB[119]. Cash Flow and Investments - The net cash flow from operating activities for 2022 was negative at approximately -¥29.23 million, a decline of 370.08% compared to ¥10.82 million in 2021[24]. - The company faced significant cash flow challenges, with negative cash flow reported in three out of four quarters of 2022[26]. - The company reported a government subsidy of 1,458,129.38 CNY in 2022, down from 2,745,483.97 CNY in 2021, reflecting a decrease in government support[30]. - The company realized an investment income of ¥129.38 million from the sale of equity in Anhui Zhongsheng Suoyuan Biotechnology Co., Ltd., significantly impacting the annual net profit[60]. - Investment income accounted for 97.62% of the total profit, primarily from wealth management product returns and the sale of equity in Anhui Zhongsheng Suoyuan Biotechnology Co., Ltd.[63]. - The net cash flow from investment activities increased by ¥76.91 million compared to the same period last year, mainly due to the redemption of bank wealth management products and term deposits maturing within one year[60]. - The net cash flow from financing activities decreased by ¥5.87 million, a decline of 103.04%, primarily due to rental expenses paid by the subsidiary Golden Designs INC. (N.A.) for warehouse and office space[60]. Market Position and Product Development - The company maintained a strong market position in the health product industry, particularly in the infrared sauna market, despite a significant decline in consumer demand in Europe due to global economic conditions[36]. - The company achieved a revenue increase in the North American market while expanding into new markets such as Australia, compensating for the downturn in Europe[38]. - The company accelerated its R&D efforts, integrating AI voice recognition technology into its infrared sauna products, and was recognized with a gold award at the Anhui Provincial Industrial Design Competition[38]. - The company is developing new air purifier products to meet diverse user needs and enhance market competitiveness[57]. - The company plans to continue expanding its market presence and developing new products, particularly through its subsidiary Golden Designs INC. (N.A.)[66]. - The company is focusing on the long-term development capability in the health industry and will selectively invest in projects with significant growth potential[90]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[117]. - New product launches are expected to contribute an additional 300 million RMB in revenue, with a focus on innovative health technology solutions[117]. - The company aims to launch three new products in the upcoming year, which are anticipated to generate 500 million RMB in sales[144]. Operational Efficiency and Cost Management - The company optimized its supply chain management to control raw material costs, which constitute a significant portion of its operating costs, thereby enhancing market competitiveness[40]. - The company will focus on cost reduction and efficiency improvement to enhance market competitiveness[89]. - The company aims to improve operational efficiency, targeting a 5% reduction in costs through process optimization[117]. - The company has set a target to reduce operational costs by 15% through efficiency improvements[144]. - The gross margin improved to 40%, up from 35% in the previous year, indicating better cost management[119]. - The gross margin improved to 45%, up from 40% in the previous year, reflecting better cost management[144]. Research and Development - The company has a robust R&D system, with 33 new patent applications and international certifications during the reporting period, totaling 304 valid patents and certifications[46]. - Research and development expenses decreased by 18.86% to ¥10,966,626.88, accounting for 2.37% of operating revenue[57]. - The company plans to increase R&D investment to enhance innovation and accelerate new product development[88]. - Investment in R&D increased by 30%, focusing on innovative health technology solutions[144]. - The company is investing 50 million in R&D for new technologies aimed at enhancing product offerings[118]. Governance and Management - The company has established a transparent and effective performance evaluation and incentive mechanism for its management team to enhance motivation and retain talent[101]. - The company adheres to strict information disclosure practices, ensuring timely and accurate communication with investors and stakeholders[102]. - The company has plans for future expansions and strategic initiatives, although specific details were not disclosed in the provided content[108]. - The company has undergone a restructuring of its organizational framework as part of its strategic adjustments[120]. - The company completed the election of the sixth board and supervisory committee, ensuring governance continuity[171]. - The company has maintained the same accounting firm, Zhongzheng Tiantong Accounting Firm, for 4 consecutive years, with an audit fee of 700,000 RMB[149]. Risks and Challenges - The company faces risks from macroeconomic conditions, including potential foreign trade order reductions due to international uncertainties, and plans to adjust product and market structures accordingly[91]. - The company is the leading enterprise in far-infrared sauna products but is affected by price competition from smaller, unregulated manufacturers, prompting a faster pace in new product development and optimization of product structure[91]. - Raw material costs constitute a significant portion of operating costs, and the company will optimize its supply chain and adopt flexible procurement strategies to mitigate risks from price fluctuations[91]. - The company will monitor exchange rate fluctuations closely, as overseas business constitutes a large portion of operations, and will implement strategies to manage foreign exchange risks[92]. Employee and Internal Control - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 3.8868 million CNY[120]. - The company has established a performance-based salary system, combining basic salary and performance bonuses to motivate employees[128]. - The company conducted various training programs to enhance the skills and management levels of its personnel, including management improvement and quality management training[129]. - The internal control system has been strengthened, with a focus on enhancing internal audit supervision and monitoring large fund transactions[132]. - The company has implemented training programs for management and employees to improve compliance awareness and internal control execution[133]. Shareholder Engagement - The company actively engages with investors through various communication channels to enhance transparency and governance[140]. - The company is committed to transparency and shareholder engagement, as evidenced by the detailed reporting of shareholder meeting outcomes and board changes[106]. - The first temporary shareholders' meeting in 2022 had an investor participation rate of 20.93% and approved the proposal to reappoint the accounting firm[106]. - The second temporary shareholders' meeting in 2022 had a participation rate of 21.68% and approved the proposal to transfer equity in a subsidiary[107]. - The third temporary shareholders' meeting in 2022 had a participation rate of 21.78% and approved the election of the sixth board of directors and supervisors[107].